Mira Pharmaceuticals (MIRA) Total Current Liabilities (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Total Current Liabilities of $702068.0 for Q4 2025, up 736.53% sequentially from $83926.0 in Q3 2025, and down 2.94% YoY from $723349.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Total Current Liabilities (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 4 years of Total Current Liabilities data on file, last reported at $702068.0 in Q4 2025.
- Quarterly Total Current Liabilities fell 2.94% year-over-year to $702068.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $702068.0 (down 2.94% YoY) and the FY2025 annual result came in at $702068.0, down 2.94% from the prior year.
- Total Current Liabilities advanced to $702068.0 in Q4 2025 per MIRA's latest filing, from $83926.0 in the prior quarter.
- The five-year high for Total Current Liabilities was $2.6 million in Q2 2023, with the low at $83926.0 in Q3 2025.
- Average Total Current Liabilities over 4 years is $784760.7, with a median of $692833.0 recorded in 2024.
- Year-over-year, Total Current Liabilities increased 29.61% in 2024 and tumbled 87.89% in 2025.
- Mira Pharmaceuticals' Total Current Liabilities stood at $1.4 million in 2022, then tumbled by 59.26% to $558097.0 in 2023, then increased by 29.61% to $723349.0 in 2024, then decreased by 2.94% to $702068.0 in 2025.
- Business Quant data shows MIRA's Total Current Liabilities at $702068.0 in Q4 2025, $83926.0 in Q3 2025, and $298459.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | 702,068.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 702,068.00 |
| Sep 30, 2025 | 83,926.00 |
| Jun 30, 2025 | 298,459.00 |
| Mar 31, 2025 | 106,173.00 |
| Dec 31, 2024 | 723,349.00 |
| Sep 30, 2024 | 692,833.00 |
| Mar 31, 2024 | 652,006.00 |
| Dec 31, 2023 | 558,097.00 |
| Sep 30, 2023 | 868,373.00 |
| Jun 30, 2023 | 2.58 Mn |
| Dec 31, 2022 | 1.37 Mn |